S P Seitz
Overview
Explore the profile of S P Seitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carini D, Kaltenbach R, Liu J, Benfield P, Boylan J, Boisclair M, et al.
Bioorg Med Chem Lett
. 2001 Aug;
11(16):2209-11.
PMID: 11514172
A new structural type of kinase inhibitor, containing a benzocarbazole nucleus, has been identified. Members of the series are selective for inhibition of the cyclin dependent kinase family of enzymes....
2.
Sielecki T, Johnson T, Liu J, Muckelbauer J, Grafstrom R, Cox S, et al.
Bioorg Med Chem Lett
. 2001 May;
11(9):1157-60.
PMID: 11354366
Quinazolines have been identified as inhibitors of CDK4/D1 and CDK2/E. Aspects of the SAR were investigated using solution-phase, parallel synthesis. An X-ray crystal structure was obtained of quinazoline 51 bound...
3.
Nugiel D, Etzkorn A, Vidwans A, Benfield P, Boisclair M, Burton C, et al.
J Med Chem
. 2001 Apr;
44(9):1334-6.
PMID: 11311054
No abstract available.
4.
Markwalder J, Christ D, Mutlib A, Cordova B, Klabe R, Seitz S
Bioorg Med Chem Lett
. 2001 Mar;
11(5):619-22.
PMID: 11266155
Studies on the biotransformation of the clinically important non-nucleoside reverse transcriptase inhibitor efavirenz have shown that oxidation and secondary conjugation are important components of the processing of this molecule in...
5.
Mutlib A, Gerson R, Meunier P, Haley P, Chen H, Gan L, et al.
Toxicol Appl Pharmacol
. 2000 Nov;
169(1):102-13.
PMID: 11076702
Efavirenz, a potent nonnucleoside reverse transcriptase inhibitor widely prescribed for the treatment of HIV infection, produces renal tubular epithelial cell necrosis in rats but not in cynomolgus monkeys or humans....
6.
Mutlib A, Chen H, Nemeth G, Markwalder J, Seitz S, Gan L, et al.
Drug Metab Dispos
. 1999 Oct;
27(11):1319-33.
PMID: 10534318
Efavirenz (Sustiva, Fig. 1) is a potent and specific inhibitor of HIV-1 reverse transcriptase approved for the treatment of HIV infection. To examine the potential differences in the metabolism among...
7.
Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors
Patel M, KO S, McHugh Jr R, Markwalder J, Srivastava A, Cordova B, et al.
Bioorg Med Chem Lett
. 1999 Oct;
9(19):2805-10.
PMID: 10522695
Efavirenz (SUSTIVA) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized...
8.
Kaltenbach 3rd R, Klabe R, Cordova B, Seitz S
Bioorg Med Chem Lett
. 1999 Aug;
9(15):2259-62.
PMID: 10465557
A series of alkyl substituted P1/P1' analogs was prepared in an attempt to increase translation of the 3-aminoindazole class of HIV protease inhibitors. Increasing the lipophilicity of the P1/P1' residues...
9.
Patel M, Kaltenbach 3rd R, Nugiel D, McHugh Jr R, Jadhav P, Bacheler L, et al.
Bioorg Med Chem Lett
. 1999 Jan;
8(9):1077-82.
PMID: 9871711
Cyclic urea SD146, a potent HIV protease inhibitor bearing a flat resistance profile, possessed poor solubility and bioavailability, which precluded further development of the compound. In an effort to improve...
10.
Patel M, Bacheler L, Rayner M, Cordova B, Klabe R, Seitz S
Bioorg Med Chem Lett
. 1999 Jan;
8(7):823-8.
PMID: 9871548
Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity. Compounds 8b, 10 (3- and 4-pyridylmethyl analogs)...